Insulet has reported a net income of $100.7m, or $1.39 per diluted share, for the fourth quarter ended 31 December 2024, a 2.5% decline compared to $103.3m, or $1.44 per diluted share, for the respective quarter in 2023.
The company’s net income for the fourth quarter of 2024 (Q4 2024) increased by 29.9% compared to $77.5m for the preceding quarter, the third quarter of 2024 (Q3 2024).
Insulet reported total revenue of $597.5m for Q4 2024, a 17.2% rise compared to $509.8m for the same quarter in 2023, and a 9.9% increase compared to $543.9m for Q3 2024.
The medical device maker reported an operating income of $109.3m for Q4 2024, a 2.7% increase compared to $106.4m for the same period in the previous year.
Insulet reported an income before tax of $111.3m for Q4 2024, a 3.2% rise compared to $107.8m for the respective quarter in 2023.
Insulet president and CEO Jim Hollingshead said: “We continue to achieve significant milestones and robust revenue growth.
“Omnipod 5 is the first and only automated insulin delivery system in the US for both type 1 and type 2 diabetes, following recent FDA clearance for the type 2 label indication.
“Insulet leads the industry, and Omnipod 5 is revolutionising diabetes care worldwide.
“I am proud of our team’s daily achievements in improving health outcomes and setting new standards in diabetes management.”
Insulet has reported a net income of $418.3m, or $5.78 per diluted share, for the full year 2024, which doubled compared to $206.3, or $2.94 per diluted share, for the full year 2023.
The company reported total revenue of $2.0bn for the full year 2024, a 22.1% rise compared to $1.69bn for the full year 2023.
Insulet reported an operating income of $308.9m for the full year 2024, a 40.4% increase compared to $220m for the full year 2023.
The medical device company reported an income before tax of $300.2m for the full year 2024, a 40% rise compared to $214.6m for the full year 2023.
